Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 17/20 | 0.53 |
| ▸ | INSR | P06213 | 16/20 | 0.53 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | PRKCG | P05129 | 2/20 | 0.46 |
| ▸ | ROS1 | P08922 | 2/20 | 0.46 |
| ▸ | FER | P16591 | 2/20 | 0.46 |
| ▸ | LTK | P29376 | 2/20 | 0.46 |
| ▸ | FRK | P42685 | 2/20 | 0.46 |
| ▸ | MST1R | Q04912 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.46 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.46 |
| ▸ | WEE1 | P30291 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590126 | 0.93 | IGF1R (0.62) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL589270 | 0.92 | IGF1R (0.67) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL589354 | 0.92 | ALK (0.56) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL591652 | 0.90 | ALK (0.52) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL15859485 | 0.88 | ALK (0.51) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL589986 | 0.88 | ALK (0.53) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL590062 | 0.87 | ALK (0.54) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL591714 | 0.87 | ALK (0.53) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL591974 | 0.86 | ALK (0.58) | IGF1RALKINSRAURKAAURKB | |
| SCHEMBL590083 | 0.86 | ALK (0.55) | IGF1RALKINSRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | claimed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | IGF1R 117/4885ALK 420/4885INSR 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.